Dr Reddy's Laboratories reported a year-on-year revenue decline of 5.6% to ₹8,071 crore (US$853 million) for Q1FY27, missing analyst estimates of ₹88.05 billion. The shortfall was driven by a ₹240 crore provision for semaglutide API-related costs and lower lenalidomide sales in North America. Despite the top-line miss, the underlying base business delivered double-digit growth across key geographies, with an adjusted EBITDA margin of 15.4% compared to the reported 12.5%. The company maintained a net cash surplus of ₹3,057 crore as of June 30, 2026.

The Board of Directors approved the unaudited standalone and consolidated financial results at their meeting held on July 22, 2026. The results were filed with stock exchanges pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chief Executive Officer Erez Israeli stated that the company plans to resume semaglutide commercial supplies by November 2026, following the resolution of API quality issues.

Financial Performance

Consolidated gross profit margin declined by 1,039 basis points year-on-year to 46.5%, impacted by lower lenalidomide sales, the semaglutide API provision, and higher solvent costs due to the Middle East conflict. Excluding the semaglutide API provision, the overall gross margin was 49.4%. Selling, general, and administrative (SG&A) expenses rose 12% year-on-year to ₹2,882 crore, primarily due to personnel increments, adverse forex movements, and elevated freight costs. Research and development spend decreased 8% year-on-year to ₹577 crore, reflecting lower biosimilars development expenditure.

Profit after tax attributable to equity holders stood at ₹443 crore (US$47 million), representing a margin of 5.5%. Diluted earnings per share (EPS) was ₹5.32. The effective tax rate for the quarter was 21.3%, lower than the 26% in the corresponding period last year, due to the reversal of previously recognized tax provisions.

Business Highlights

Dr Reddy's achieved several strategic milestones, including the first-to-market launch of bosutinib 400mg in the US with 180-day exclusivity. The company became the first to launch generic semaglutide injection for Type 2 Diabetes in Canada and introduced oral semaglutide in India. Emerging Markets revenue grew 31% year-on-year to ₹1,833 crore, while India revenue rose 17% to ₹1,718 crore. North America generics revenue declined 41% year-on-year to US$236 million, largely due to lenalidomide.

On the regulatory front, the USFDA issued a Form 483 with seven observations following a Pre-Approval Inspection at the Bachupally biologics facility in June 2026. Management confirmed that responses were submitted within the stipulated timeline and expressed confidence in receiving approval for abatacept by December 2026.

What the Numbers Show

The divergence between reported EBITDA margins (12.5%) and adjusted margins (15.4%) highlights significant drag from one-time charges rather than operational inefficiency. While North America revenue decreased sharply, Emerging Markets and India demonstrated robust growth, indicating a successful geographic diversification strategy. The company’s guidance for full-year capex of approximately ₹1,800 crore suggests continued investment in biosimilars and peptides, despite current profitability pressures from these segments.

Shareholders of Dr Reddys Laboratories approved a final dividend of ₹8 per equity share for the financial year ended March 31, 2026, during its 42nd Annual General Meeting held on July 23, 2026. The virtual meeting, conducted via Video Conferencing and Other Audio-Visual Means (OAVM), also witnessed the re-appointment of Chairman K Satish Reddy and the appointment of Deloitte Haskins & Sells LLP as statutory auditors for a five-year term. The approval of these key governance and shareholder return measures underscores continued investor confidence in the company’s leadership and financial stewardship.

The meeting commenced at 11:00 AM IST with 86 members holding 22,25,59,764 shares in attendance, satisfying the quorum requirements under Article 70 of the Articles of Association. Chairman K Satish Reddy presided over the proceedings, which were scrutinized by Atul Mehta of Mehta & Mehta, Company Secretaries. In compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, voting was conducted through remote e-voting from July 19 to July 22, 2026, and via electronic voting during the AGM. All seven resolutions on the agenda were declared passed by the requisite majority.

Key Resolutions Passed

The Board of Directors sought shareholder approval for several ordinary and special resolutions. The dividend declaration received near-unanimous support, with 99.99% of votes cast in favor. Similarly, the adoption of the audited financial statements for FY26 passed with 99.99% approval. The re-appointment of K Satish Reddy, who retires by rotation, secured 99.38% support.

Governance and Auditor Appointments

The company appointed M/s. Deloitte Haskins & Sells LLP as its statutory auditors for a period of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM. This resolution passed with 99.98% support. Additionally, the remuneration payable to cost auditors M/s. Sagar & Associates for the financial year ending March 31, 2027, was ratified with 99.99% approval.

In terms of board composition, shareholders approved the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five years, effective from January 7, 2027, to January 6, 2032. The resolution received 97.27% support. The company also appointed Mr. Srikanth Velamakanni as an Independent Director for a five-year term, effective from July 1, 2026, to June 30, 2031. This special resolution passed with 91.35% of votes in favor.

What the Numbers Show

The voting patterns reveal strong institutional alignment with management proposals, particularly on financial and audit matters. The promoter group, holding 22,23,05,640 shares, voted unanimously in favor of all resolutions. Public institutions accounted for approximately 91% of the total votes polled, indicating high engagement from large investors. While the appointment of Srikanth Velamakanni faced notable dissent (8.65% against), it still comfortably met the three-to-one majority requirement for special resolutions, reflecting broad-based acceptance of the board’s governance strategy.